The authors found that 1-month postoperative endothelial cell loss (ECL) was higher with FLACS with no difference in postoperative central corneal thickness (CCT), without mentioning the intergroup P value. We applied parametric statistics to arrive at the intergroup P = 0.58 comparing the final CCT at 4 weeks. However, a percentage change of CCT in each group with comparative statistics should have been mentioned to arrive at the abovementioned conclusion.
Although the authors have found a significantly higher ECL with FLACS, they have not mentioned the phacotorsional energy measured as cumulative dissipated energy which has significant effect on ECL apart from fluid usage or effective phaco time. [2] Phaco energy and time are the most important factors for endothelial damage, and FLACS may be beneficial by omitting need to sculpt and/or chop the nucleus, with similar results as studies comparing phaco chop with divide-conquer technique. [3, 4] They have also not specified which mode of phacoemulsification was used; however, they did mention about the effective phaco time being lesser in FLACS (P < 0.001). The meta-analysis by Chen et al. did not find any reduction in ECL or CCT rise with FLACS as against one by Popovic et al. which found a significant reduction of ECL with no difference in surgical time. [5] In addition, an analysis by grade of cataract may be undertaken to further analyze the ECL in the harder grades over the lower ones to finally conclude, in which group of patients FLACS may be effectively a better option. We await a response eagerly.
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There are no conflicts of interest. laser-assisted cataract surgery versus 2.2 mm clear corneal phacoemulsification Sir, Thank you for taking interest in our article [1] and sharing your opinion in this context. [2] We noted that there was no significant change in the postoperative pachymetry/central corneal thickness at 4 weeks in each group. The intergroup P value for the change in pachymetry was 0.962 with 0.6% change in pachymetry in femtosecond laser-assisted cataract surgery (FLACS) group and 0.7% change in control group. Hence, we concluded that there is no significant difference in the change of pachymetry/central corneal thickness in our study between the groups. A study conducted by Edwards et al. [3] on conventional versus LensAR FLACS also concluded that there is no significant difference in the corneal thickness between both the groups.
Letters to the Editor
We have mentioned in our paper that the phaco technique used was direct phaco chop technique. However, we agree that cumulative dissipated energy could also have been additionally analyzed. Although we did match the grade of cataracts in the two groups, we have not analyzed the endothelial cell loss by cataract grade because the cataract subgroups were unequally distributed and our study did not had enough statistical power for analysis. These are aspects which could be looked at in further studies.
Sir,
We read with interest the article entitled, "Fungal keratitis: The Aravind experience" by Prajna et al. [1] First, in the compilation of the clinical articles published on this topic by the researcher from that institution, shown in the Fig. 1 included in the article by Prajna et al., an older study than those referred (a masked, randomized clinical trial of three concentrations of chlorhexidine compared with natamycin 5%, published in 1997) is missing from the list. In fact, that study showed that chlorhexidine might be superior to natamycin. Compared with the response to natamycin as the referent, the relative efficacy was 1.17 with chlorhexidine 0.05%, 1.43 with 0.1%, and reached 2.00 with 0.2%. The superiority of 0.2% chlorhexidine over natamycin was statistically significant (relative efficacy 2.20, P = 0.043) in patients not having had prior antimycotic medication. [2] Since the investigators did not mention chlorhexidine 0.2% in their recent review, we wonder if they had any posterior negative experience using this substance in fungal keratitis.
The recent studies Mycotic Ulcer Treatment Trial I (MUTT I) and MUTT II, performed also by researchers from Aravind Eye Hospital, showed that topical natamycin was superior to topical voriconazole. [3, 4] Since in the clinical trial from 1997, it was found that chlorhexidine 0.2% could be twice as effective as natamycin, would not it be worth conducting a new study with chlorhexidine and natamycin? Not only to probably corroborate the earlier findings from 1997 but also to evaluate a possible synergy between them? Furthermore, in the recently published results from the study MUTT II (both for all cases of keratomycosis and for Fusarium keratitis), the researchers from Aravind indicated that all patients received topical voriconazole, 1%, and that after the results of the MUTT II study became available, topical natamycin, 5%, was added for all patients. [4, 5] It would be interesting to know if they have found any kind of synergy between these two medications. In the current protocol of their hospital, do they use both topical medications concurrently?
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